GLP-1 medications like Ozempic and Wegovy can reduce appetite and lead to nutritional gaps. Here is what the research says and how to stay protected.
The FDA warned Novo Nordisk for not reporting deaths and serious side effects tied to its GLP-1 medications. Here is what happened.
Products marketed as "natural GLP-1s" and peptide supplements are everywhere. Here is what the science says and how to protect yourself.
New research links GLP-1 medications to reduced addiction risk. See what the WashU and JAMA studies found and what clinical trials are underway.
Research shows weight regain after stopping Ozempic or Wegovy. See how fast it happens, what else reverses, and what you can do now to keep results.
See what a full day of eating looks like on a GLP-1 with protein, fiber, and carb targets. Sample meals, macros, and tips for Ozempic users.
Novo Nordisk and Hims struck a deal on Ozempic and Wegovy pricing. See what it means for GLP-1 costs, compounded access, and your options.
GLP-1 shots cost under $5 to make but sell for $900+. See what drives the price, whether it's justified, and how pricing is changing in 2026.
Worried about GLP-1 side effects? Learn what’s common, how often it happens, and when symptoms usually start.
India’s GLP-1 patent expiry may lower prices there first. Learn what it could mean for US access and affordability.
Confused by GLP-1, GLP-2, and GIP? Learn what each term means and how they relate to weight and diabetes treatment.
Major GLP-1 and obesity drug trials are finishing in 2027. Here’s what they’re studying and what it could mean for access and affordability.
